Andrea Corona

New York, United States

Senior Editor at Pharma Manufacturing

Currently: Sr. Editor @PharmaMfg Previously: Associate Editor @biocompare & Digital @scifri

Featured in: Favicon

pharmamanufacturing.com Favicon

grist.org

gainesvilletimes.com Favicon

biocompare.com Favicon

chicmagazine.com.mx Favicon

japha.org

revistafama.com

Articles

Gilead to expand US manufacturing with $11B investment in new and upgraded facilities

1 month ago | pharmamanufacturing.com | Andrea Corona

Gilead Sciences has announced a multi-year, multi-billion-dollar investment plan designed to strengthen its U.S.-based manufacturing and research infrastructure. The initiative includes $11 billion in new capital and operational expenditures, building on a previously announced $21 billion spend through 2030. Combined, the company projects these efforts will generate $43 billion in economic impact over the next five years.
Bristol Myers Squibb to invest $40B in US R&D and manufacturing

1 month ago | pharmamanufacturing.com | Andrea Corona

Bristol Myers Squibb has announced plans to invest $40 billion in the United States over the next five years, focusing on expanding its domestic research, development, and manufacturing capabilities. The investment will be directed toward advancing U.S.-based research and development, building out domestic manufacturing infrastructure, and incorporating emerging technologies such as artificial intelligence and machine learning to accelerate drug discovery and development.
Bristol Myers Squibb to invest $40B in US R&D and manufacturing

1 month ago | pharmamanufacturing.com | Andrea Corona

Bristol Myers Squibb has announced plans to invest $40 billion in the United States over the next five years, focusing on expanding its domestic research, development, and manufacturing capabilities. The investment will be directed toward advancing U.S.-based research and development, building out domestic manufacturing infrastructure, and incorporating emerging technologies such as artificial intelligence and machine learning to accelerate drug discovery and development.
10 companies hit by FDA’s 2025 inspection crackdown

2 months ago | pharmamanufacturing.com | Andrea Corona

Amid looming tariff threats and a war cry by President Donald Trump to return manufacturing to the United States, the FDA continues to face persistent challenges overseeing foreign drug manufacturing, particularly in China and India. While the agency has ramped up post-pandemic inspections and introduced new tools such as unannounced visits, its ability to consistently monitor global supply chains remains limited by staffing gaps and oversight inconsistencies.
Eli Lilly, Merck, Purdue University team to push innovation in sterile injectables

Mar 11, 2025 | pharmamanufacturing.com | Andrea Corona

Sterile injectable drugs account for over 40% of new drug approvals, but their production remains slow, costly, and heavily regulated.
2025 pharma predictions

Mar 4, 2025 | pharmamanufacturing.com | Andrea Corona

Pharma stands at the threshold of 2025 with a blend of cautious optimism and strategic urgency. Scientific breakthroughs, regulatory shifts, and technological advancements continue to reshape the sector, forcing companies to adapt to new realities. From cutting-edge drug delivery systems to AI-driven research models, the coming year will demand agility, innovation, and forward-thinking strategies.
While etherna is rethinking RNA manufacturing, don’t call it a CDMO

Mar 3, 2025 | pharmamanufacturing.com | Andrea Corona

In 2013, etherna went all in on a big idea: develop RNA-based therapeutics in an era when lipid nanoparticles (LNPs) were barely a footnote in drug development. At the time, the industry was still relying on naked RNA, unprotected and vulnerable to degradation, as the go-to delivery method. Etherna’s initial approach focused on ex vivo treatments, engineering cells outside the body before reinfusing them into patients.
KBI Biopharma: From centrifuge innovation to CDMO leader

Feb 27, 2025 | pharmamanufacturing.com | Andrea Corona

KBI Biopharma didn’t set out to be a contract development and manufacturing organization (CDMO) giant — it started with a centrifuge. Not just any centrifuge, but a vertical, disposable model developed by Kinetic Biosystems Incorporated in Georgia.
6 potential drug approvals to watch for in 2025

Jan 9, 2025 | pharmamanufacturing.com | Andrea Corona

This year, the FDA is expected to approve several new therapies that highlight the increasing complexity of pharmaceutical manufacturing. From biologics to treatments for rare diseases, these drugs will bring unique production challenges that require advanced technologies and precise processes. Here’s a look at six anticipated approvals in 2025.
Pharma’s molecular glue garden

Dec 11, 2024 | pharmamanufacturing.com | Andrea Corona

In the 1950s, thalidomide was as a sedative and quickly became popular for treating morning sickness in pregnant women. However, its widespread use was then linked to severe birth defects in thousands of babies, prompting its withdrawal from the market in the early 1960s. While the tragedy significantly impacted drug regulation and safety protocols worldwide, in the decades that followed, thalidomide found a remarkable second life in medicine.